Recall Register

Drug recall: Adrenalin Chloride Solution (Epinephrine Nasal Solution, USP), 30mg/30mL (1mg/mL), packaged in 30 mL vials…

Class I FDA enforcement event 96013. Recall start date: . Status in the FDA record: Ongoing.

Reason for recall, in the words of FDA

Labeling: Not Elsewhere Classified: misleading label similar in appearance to the FDA-approved drug product Adrenalin (epinephrine injection, USP)

Class I, in the words of FDA

a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death

ENDO USA, Inc. started this drug recall on 20 Dec 2024. The firm address in the FDA record is in Rochester, MI. FDA put the recall in Class I. FDA event 96013 has 1 product record. The first FDA enforcement report date is 12 Feb 2025. The record gives the status Ongoing.

It is important to note that most of the time recall classifications are determined after the recalling firm provides all of the information needed to determine the risk posed to public health. The classification and posting in the FDA Enforcement Report should not be seen as an expansion or change to a firm’s voluntary public warning.

FDA publishes these words. Source: FDA, Enforcement Reports, Important Note, read on . openFDA export of .

Distribution

In the words of FDA.

USA nationwide.

Recalling firm

ENDO USA, Inc., Rochester, MI.

Recalling firm: The firm that the FDA record names for a recall.

FDA records how the recall started: Voluntary: Firm initiated.

Products

1 product record in the event.

FDA event 96013: product records
Recall numberProductQuantityClassStatusReport date
D-0223-2025Adrenalin Chloride Solution (Epinephrine Nasal Solution, USP), 30mg/30mL (1mg/mL), packaged in 30 mL vials, Distributed by: Par Pharmaceutical, Chestnut Ridge, NY 10977, NDC 42023-103-0144,397 amber glass vialsClass IOngoing12 Feb 2025

openFDA, about the status: FDA does not update the status of a recall after the recall has been classified according to its level of hazard. As such, the status of a recall (open, completed, or terminated) will remain unchanged after published in the Enforcement Reports. Source: openFDA, Drug Recall Enforcement Reports, Disclaimer.

Enforcement report: The FDA publication that lists recalls. It has one record for each product of a recall.

Enforcement event: All the product records that have one FDA event number. This site shows one event on one page.

Class I: The highest of the three FDA recall classes.

The event in context

Drug events that started in 2024
319
Share of these events in Class I
13%
Product records in this event
1Median of the firm: 1
Events of the firm on the register
5

Other events of the firm

Official channels

Cite this page

Recall Register. FDA enforcement event 96013. https://recallregister.com/fda/i/96013/. Source: openFDA enforcement reports. Data through .

Sources

Source
openFDA drug enforcement reports
Licence
CC0 1.0
Export date
28 Sep 2026
Newest FDA report date on the register
23 Sep 2026

FDA has one record for each product. This site puts the records with the same event number on one page. The class of the event is the highest class of its records. How the register is made. Report an error.

Questions

Where was the product distributed?
The FDA record gives this distribution: USA nationwide.
What quantity of product is in FDA event 96013?
The FDA record gives this quantity: 44,397 amber glass vials
How did the recall start?
The FDA record says: Voluntary: Firm initiated
How many drug recalls of 2024 have the same class?
13% of the 319 drug events that started in 2024 are in Class I.